Oral News and Research

RSS

Florida Judge signals he will likely allow some parts of states' health law challenge to proceed

Bloomberg: "U.S. District Judge Roger Vinson in Pensacola said today he will make a decision by Oct. 14 on whether the states have jurisdiction to sue. He told lawyers he would probably dismiss part of the suit, while allowing other claims to proceed." The states involved in the lawsuit maintain that the federal government's "requirement that people buy health insurance" goes beyond Congress' constitutional powers.

15 Sep 2010

Unsuccessful gum-disease treatment linked to preterm birth

A collaboration led by a periodontal researcher from the University of Pennsylvania School of Dental Medicine has found a possible link between the success of gum-disease treatment and the likelihood of giving birth prematurely, according to a study published in the journal BJOG: An International Journal of Obstetrics and Gynaecology.

15 Sep 2010

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

The recent news that Michael Douglas has been diagnosed with stage 4 throat cancer has raised public awareness of head and neck cancer. What causes throat cancer and what are the symptoms? Are there ways to prevent or reduce the risk of throat cancer? How is the human papillomavirus (HPV) related to oral cancer?

14 Sep 2010

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Gentium S.p.A. today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.

14 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Relypsa completes $70M Series B financing

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million. OrbiMed Advisors, LLC, led the financing with participation from existing Relypsa investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners.

13 Sep 2010

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis will be presented at the Annual Congress of the European Respiratory Society, to be held September 18-22 in Barcelona, Spain.

13 Sep 2010

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

Oral health impacts systemic diseases: Report

It's not news that there is a significant link between one's oral health and overall health. Though studies are ongoing, researchers have known for quite some time that the mouth is connected to the rest of the body.Your mouth is the entry point of many bacteria,said Dr. Steven Grater, Pennsylvania Dental Association (PDA) member and general dentist from Harrisburg. To keep this bacteria from going into your body, cleaning your mouth (brushing, flossing and rinsing) is necessary.

13 Sep 2010

High estrogen levels in female athletes associated with higher risk of injury

In female athletes with chronically higher estrogen levels, differences in the mechanical properties of tendons may lead to a higher risk of injury, according to a study in The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association. The journal is published by Lippincott Williams & Wilkins , a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

10 Sep 2010

BPA detectable in saliva of children for up to three hours after completion of dental work

Researchers from Mount Sinai School of Medicine have found that bisphenol A (BPA) released from some plastic resins used in pediatric dentistry is detectable in the saliva after placement in children's mouths. BPA is a widely used synthetic chemical that has been associated with changes in behavior, prostate and urinary tract development, and early onset of puberty. The findings are published in the current issue of Pediatrics.

10 Sep 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Florida-based biopharmaceutical company Oragenics, Inc. has announced the continued retail expansion of its oral care probiotics EvoraPlus and EvoraKids™ with an initial order from Harris Teeter. It is anticipated that the products will be available at Harris Teeter stores in September 2010.

10 Sep 2010

Oral News and Research

Florida Judge signals he will likely allow some parts of states' health law challenge to proceed

Unsuccessful gum-disease treatment linked to preterm birth

Dana-Farber doctor hosts live program on Twitter to discuss head and neck cancers

Gentium announces defibrotide presentations at 33rd World Congress of International Society of Hematology

Emergency physicians to present research studies at Research Forum 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Relypsa completes $70M Series B financing

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Oral health impacts systemic diseases: Report

High estrogen levels in female athletes associated with higher risk of injury

BPA detectable in saliva of children for up to three hours after completion of dental work

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News